Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Background/Aims Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited. This study aims to determine hepatitis B surface antigen (HBsAg) screening rates, HBV prevalence, and the rate of significant hepatitis caused by HBVr in SOM patients undergoing CMT.
Methods Based on the Oncology unit’s registration database from 2009–2013, we retrospectively reviewed records of all SOM patients ≥18 years undergoing CMT at Songklanagarind Hospital who were followed until death or ≥6 months after CMT sessions. Exclusion criteria included patients without baseline liver function tests (LFTs) and who underwent CMT before the study period. We obtained and analyzed baseline clinical characteristics, HBsAg screening, and LFT data during follow-up.
Results Of 3,231 cases in the database, 810 were eligible. The overall HBsAg screening rate in the 5-year period was 27.7%. Screening rates were low from 2009–2012 (7.8–21%) and increased in 2013 to 82.9%. The prevalence of HBV among screened patients was 7.1%. Of those, 75% underwent prophylactic antiviral therapy. During the 6-month follow-up period, there were three cases of significant hepatitis caused by HBVr (4.2% of all significant hepatitis cases); all were in the unscreened group.
Conclusions The prevalence of HBV in SOM patients undergoing CMT in our study was similar to the estimated prevalence in general Thai population, but the screening rate was quite low. Cases of HBVr causing significant hepatitis occurred in the unscreened group; therefore, HBV screening and treatment in SOM patients should be considered in HBV-endemic areas.
Citations
Citations to this article as recorded by
Hepatitis B Virus Screening Prior to Chemotherapy in Patients with Solid Organ Malignancy at the Brazzaville University Hospital Pérès Mardochée Motoula Latou, Evodie Syntyche Motoula Latou, Alexis Fortuné Bolenga Liboko, Eliane Ndounga, Judith Nsonde Malanda, Blaise Irénée Atipo Ibara Open Journal of Gastroenterology.2025; 15(07): 390. CrossRef
Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysis Soe Thiha Maung, Natee Deepan, Pakanat Decharatanachart, Roongruedee Chaiteerakij Asia-Pacific Journal of Clinical Oncology.2024; 20(3): 335. CrossRef
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis Natee Deepan, Soe Thiha Maung, Pakanat Decharatanachart, Roongruedee Chaiteerakij Seminars in Oncology.2024;[Epub] CrossRef
Viral hepatitis B in patients with hematological malignancies (Overview) Sidorkevich SV, Chebotkevich VN, Kuleshova AV, Kajtandzhan EI, Bessmeltsev SS Archives of Hepatitis Research.2023; 9(1): 001. CrossRef
Systematic review of seroprevalence of markers of hepatitis B, C and HIV among oncohematological patients A.V. Satsuk, G.G. Solopova, A.A. Ploskireva, V.G. Akimkin Clinical Microbiology and Antimicrobial Chemotherapy.2023; 25(2): 131. CrossRef
Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin James Crosby, Forrest Smith, Subramanya Shyam Ganti, Nagabhishek Moka, Samuel Bailey Journal of Investigative Medicine High Impact Case Reports.2022;[Epub] CrossRef
HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program Supinya Sono, Jirayu Sae-Chan, Apichat Kaewdech, Naichaya Chamroonkul, Pimsiri Sripongpun, Jason T. Blackard PLOS ONE.2022; 17(6): e0270458. CrossRef
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
Citations
Citations to this article as recorded by
Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap Alimentary Pharmacology & Therapeutics.2026; 63(7): 945. CrossRef
Urinary Levels of Neutrophil Gelatinase-associated Lipocalin and Cystatin C in Patients with Hepatitis B on Tenofovir Treatment Shivani Rani, Himanshu Dandu, Ambuj Yadav, Mahak Lamba, Amit Goel, Wahid Ali, Virendra Atam, Sumit Rungta, Medhavi Gautam, Atin Singhai Journal of The Association of Physicians of India.2025; 73(2): 13. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B Young Youn Cho, Young Chang, Joon Yeul Nam, Hyeki Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2020; 14(2): 225. CrossRef
Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn, Seung Up Kim Journal of Viral Hepatitis.2020; 27(9): 932. CrossRef
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue Sung Won Lee, Seung Up Kim Alimentary Pharmacology & Therapeutics.2020; 52(5): 889. CrossRef
Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients Sang Jin Kim, Jinsoo Rhu, Seo Hee Lee, Jong Man Kim, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh Annals of Surgical Treatment and Research.2020; 99(3): 180. CrossRef
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B A Young Cho, Ju Hwan Oh, Hee-Chan Moon, Gum Mo Jung, Young Suk Lee, Yeong Jin Choi, In O Sun, Kwang Young Lee Kidney Research and Clinical Practice.2020; 39(3): 373. CrossRef
Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice Eungyeong Jang, Jong Kil Lee, Kyung-Soo Inn, Eun Kyoung Chung, Kyung-Tae Lee, Jang-Hoon Lee Healthcare.2020; 8(4): 417. CrossRef
Application of High-Performance Liquid Chromatography for Simultaneous Determination of Tenofovir and Creatinine in Human Urine and Plasma Samples Patrycja Olejarz, Grażyna Chwatko, Paweł Kubalczyk, Krystian Purgat, Rafał Głowacki, Kamila Borowczyk Pharmaceuticals.2020; 13(11): 367. CrossRef
Tenofovir-Associated Acute Kidney Disease: Is it Different in HIV- and HBV-Infected Patients? Fatemeh Ghasemi, Mohammadreza Salehi, Niloofar Khoshnam Rad, Hossein Khalili American Journal of Therapeutics.2019; 26(5): e639. CrossRef
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization Young Youn Cho, Young Hwan Choi, Su Jong Yu, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon Journal of Liver Cancer.2019; 19(2): 128. CrossRef
Effect of tenofovir on renal function in patients with chronic hepatitis B Woo Jin Jung, Jae Young Jang, Won Young Park, Soung Won Jeong, Hee Jeong Lee, Sang Joon Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Suyeon Park, Baigal Baymbajav Medicine.2018; 97(7): e9756. CrossRef
Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients H. J. Tsai, Y. W. Chuang, S. W. Lee, C. Y. Wu, H. Z. Yeh, T. Y. Lee Alimentary Pharmacology & Therapeutics.2018; 47(12): 1673. CrossRef
First
Prev
